SCHEMBL10185245

SCHEMBL10185245

CCOC(=O)c1cn2c(Cl)c(C)nc2cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.51
CYP1A2 P05177 2/20 0.45
AKT1 P31749 1/20 0.45
AKT2 P31751 1/20 0.45
NOTUM Q6P988 1/20 0.43
MAPK1 P28482 2/20 0.42
GABRA2 P47869 3/20 0.41
GABRB2 P47870 3/20 0.41
KDM4E B2RXH2 4/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 2/20 0.41
POLB P06746 1/20 0.41
LMNA P02545 1/20 0.41
DPP4 P27487 1/20 0.40
DPP8 Q6V1X1 1/20 0.40
DPP9 Q86TI2 1/20 0.40
GLA P06280 1/20 0.40
KMT2A Q03164 2/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31244495 0.84 GAA (0.51) GAACYP1A2AKT1AKT2NOTUM
SCHEMBL10185248 0.84 GAA (0.51) GAACYP1A2AKT1AKT2MAPK1
SCHEMBL15717868 0.76 KDM4E (0.53) GAACYP1A2AKT1AKT2NOTUM
SCHEMBL10185249 0.76 GAA (0.44) GAACYP1A2AKT1AKT2MAPK1
SCHEMBL15717521 0.75 GAA (0.50) GAACYP1A2AKT1AKT2NOTUM
SCHEMBL15739861 0.74 AKT1 (0.51) GAACYP1A2AKT1AKT2GABRA2
SCHEMBL11369182 0.74 GAA (0.52) GAACYP1A2NOTUMGABRA2GABRB2
SCHEMBL15176026 0.71 KDM4E (0.62) GAACYP1A2GABRA2GABRB2KDM4E
SCHEMBL26079081 0.71 GAA (0.56) GAACYP1A2GABRA2GABRB2KDM4E
SCHEMBL118187 0.71 GAA (0.75) GAACYP1A2MAPK1GABRA2GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. 2012-02-16 US disclosed
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS BRAF, RAF1, ARAF GAA 1958/4885CYP1A2 2345/4885AKT1 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.